GRI Bio, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for GRI, updated each market day.
GRI AI Sentiment
AI sees no strong directional signal for GRI Bio, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About GRI Bio, Inc. Common Stock
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Sector
Exchange
Market Cap
$3,410,268
Cap Tier
Employees
5
Headquarters
LA JOLLA, CA
Listed Since
April 24, 2023
Website
GRI Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
GRI Volatility
GRI Bio, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
